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Abstract. KAI1, also known as CD82, has been shown to have
a potential impact on the invasiveness of cancer cells. In the
present study, expression pattern of KAI1, both at tran-
scription and translation levels and the potential clinical
value of the expression were explored in a cohort of normal
and ductal mammary cancer tissues (n=71). A marked
reduction of KAI1 transcript was observed in invasive ductal
breast tumours as compared to normal tissues. Expression of
KAI1 protein was higher in normal tissues as compared to
tumour samples. Though no significant difference of KAI1
expression between different grades of tumour was observed
(p=0.064), significant correlation of TNM staging with KAI1
expression has been observed in invasive ductal breast cancer
patients (p=0.045). Additionally, it was also observed that
patients showing higher expression of KAI1 had a longer
10-year survival rate as compared to a low level or com-
pletely negative expression KAI1 (p=0.0136). KAI1 inverse
correlation with tumour progression may be used as a strong
prognostic marker.
Introduction
Breast cancer is one of the most frequently occurring cancers
amongst females across the globe. According to the American
Cancer Association, women of all origin have a substantial
risk of developing breast cancer (incidence rate in Caucasians
130.8; African Americans 111.5; Asian Americans and
Pacific islanders 91.2; American Indians 74.4 per 100,000).
Metastasis is the primary cause of death for the patients.
Metastasis, a complex biological and clinical event, is
influenced by a number of molecules. These molecules, by
acting on the breast cancer cells and stromal cells, impact on
the cellular behaviours of cancer cells during the metastatic
process. KAI1 (Kang ai as from Chinese meaning anticancer)
is one of these molecules and is a member of the tetraspanin
family that was first identified in a T-cell activation study
(1). Metastasis suppression induced by this gene in prostate
cancer was explored later on by somatic cell hybridization of
highly metastatic and non-metastatic rat prostate cancer cells
(2). KAI1 is also termed as SAR2 leukocyte surface antigen
R2 and suppressor of tumorigenicity 6 (ST6). Dong et al,
identified the location of KAI1 gene on chromosome 11p with
10 exons and 9 introns spanning ~80 kb (3). KAI1 protein
exists in two isoforms, with 267 residues in isoform-1 and
242 residues in isoform-2 (4). KAI1 plays an important role
in cancer largely due to its interesting relationship with other
molecules that are strongly linked to the function of cancer
cells.
It has been established in recent years that apart from
interacting with other members of the tetraspanin family,
KAI1 protein molecule interacts with integrins and epidermal
growth factor receptor (EGFR) (5,6), in doing so KAI1 aids
the internalisation of integrins and EGFR. This may result in
loss of reduction of integrins and EGFR, pivotal regulators of
cell adhesion and growth in breast cancer. Altered expression
of KAI1 ultimately leads to decrease in adhesion and increase
invasiveness of cancer cells. KAI1 has an ectopic effect on
adhesion by strengthening the interaction among E-cadherin
with ß-catenins and reduces the chances of cellular dissem-
ination for the primary tumour (7).
Expressional regulation of these genes in relation to various
clinical parameters during cancer progression have been
reported in prostate cancer (8), breast (9,10), lung (11), ovarian
(12), gastric (13,14), pancreatic (15), oesophagus (16), bladder
(17) and cervical cancer (18). Inverse correlation of KAI1
expression with respect to cancer progression has been
observed in all these studies. It has been observed that a
decreased expression of KAI1 is associated with poor
prognosis. The aim of the present study was not only to screen
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expression levels of KAI1 molecule in breast cancer patients
but also to find a correlation (if any) with the tumour stage,
as well as long-term survival of the patients.
Materials and methods
RNA-extraction kits and Mastermix for routine PCR and
quantitative PCR were obtained from AbGene (Surrey, UK).
PCR primers were designed using Beacon designer (Palo
Alto, CA, USA) and synthesised by Invitrogen (Paisley,
UK). Molecular biology grade agarose and DNA ladder were
purchased from Invitrogen.
The first strand cDNA synthesis kit was purchased from
Sigma Chemical Ltd. (Dorset, UK). A universal IHC kit was
purchased from Vector Laboratories (Peterborough, UK).
Low fluorescent 96-well plates were obtained from AbGene
and sealing film was purchased from BioRad (Hemel
Hempstead, UK).
Breast sample collection. Ductal breast cancer tissues (n=71)
and normal tissues (n=31) that were free from cancer cells
were collected (with approval from the local ethics committee)
immediately after surgery and stored at -80˚C until required.
These patients were routinely followed clinically after surgery.
Median follow-up was 120 months. Histopathological features,
tumour grade, tumour staging and the prognostic index for
the patients are shown in Table I.
Tissue processing. Frozen sections of breast tissues were cut
using cryostat at a thickness of 5-10 μm and were stored at
-20˚C (19,20). Approximately 15-20 sections from each breast
tissue sample were homogenized using a hand held homo-
genizer in ice-cold RNA extraction buffer. Concentration of
RNA was confirmed by using UV spectrophotometer (Wolf
Laboratories, York, UK).
cDNA synthesis and analysis of the KAI1 transcript. Reverse
transcription was carried out by using 1 μg of total RNA
from each sample. Oligo-dT primer present in the RT kit
was used and cDNA was prepared according to the manu-
facturer's instructions. Polymerase chain reaction was
preformed using this synthesized cDNA. Reaction conditions
were 95˚C for 5 min; 94˚C for 20 sec; 55˚C for 30 sec, 72˚C
for 1 min for 38 cycles with 10 min final extension at 72˚C.
The following primers were used in the reaction, KAI1
forward: 5'CTGTACTTTGCTTTCCTGCT'3 and KAI1
reverse: 5'CTGTAGTCTTCGGAATGGAC'3. ß-actin was
used as internal control in the experiment. Amplified products
were visualized, following staining with 2% agarose gel.
Quantitative PCR analysis. Transcripts of all patients were
analysed by using IQ real-time quantitative Thermal cycler
(BioRad). Specific pairs of primers were designed using Beacon
Designer and synthesized by Invitrogen. Sense primers for
KAI1 (5'CATTCGAGACTACAACAGCA3') and antisense
primer including Z sequence (complementary to universal
probe 5'ACTGAACCTGACCGTACATCCAGTTGTAGA
AGCTGACC'3) were used for its detection. GAPDH was used
as an internal control in this quantitative reaction (primer pair
for GAPDH: 5'CTGAGTACGTCGTGGAGTC'3 and 5'ACT
GAACCTGACCGTACACAGAGATGATGACCCTTTTG'3).
The reaction was carried out using the following reaction
conditions: Hot-start Q-master mix (Abgene), 10 pmol of
specific forward primer, 1 pmol of antisense primer
(containing Z sequence). A probe of 100 pmol concen-
tration of (6 carboxy-fluorescein FAM) was used. The
reaction conditions were 94˚C for 120 min; 94˚C for 150 sec,
55˚C for 400 sec and 72˚C for 200 sec with 60 cycles. The
data generated was first normalized with the GAPDH
molecule.
Immunohistochemical staining. Immunohistochemical
staining was done using both tumour and normal frozen
sections of 6 μm thickness. The sections were mounted on
Super Frost Plus microscopic slides and air dried for 20-30 min.
These fixed tissue sections were treated in 50% methanol
and 50% acetone for 15 min. Sections were then air dried for
10 min and stored at -20˚C (wrapped in foil) for further use
or immediately stained. These air dried samples were placed
in PBS for 5 min to rehydrate, followed by blocking using a
buffer with 10% horse serum. These sections were then treated
with primary antibodies. Antibodies used for KAI1 were
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA)
raised in rabbit. After a 1-h incubation of primary antibodies
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Table I. Clinical pathological features of the cohort of the ductal carcinoma of the breast.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Groupings Number of samples
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Grade Grade-1 Grade-2 Grade-3
n=9 n=24 n=38
TNM staging TNM1 TNM2 TNM3/4
n=38 n=27 n=6
NPI status NPI <3.4 NPI 3.4-5.4 NPI >5.4
n=35 n=27 n=9
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Clinical outcome Disease-free With metastasis With local recurrence Died of breast cancer
N=52 N=7 N=4 N=8
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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the slides were subjected to 4 washes with PBS and then
treated in universal multi-link biotinylated secondary anti-
body. After 30 min of incubation, 4 washes with PBS were
performed on these slides. Slides were then treated with
avidin biotin complex (ABC, Vector Labs, UK). Diamino-
benzidine tetrahydrochloride [3,3-diaminobenzidine (DAB)
purchased from Sigma] was added for 5 min to detect the
bound antibody. The slides were washed with water for 5 min
and treated with Mayer's haematoxylin for 1 min followed by
a further wash with water for 10 min. The slides were then
treated with methanol (3 times) and clearing in 2 changes of
xyline before mounting under a cover slip. PBS is used as
negative control in this experiment. Each experiment was
repeated thrice for conclusive results.
Statistical analysis was carried out using Mann-Whitney U
test (IQR) and survival analysis by Kaplan Meier survival
analysis, using SPSS package (SPSS version 16).
Results
Distribution of KAI1 in mammary cells. After immunohisto-
chemical staining, the presence of KAI1 protein was confirmed
in breast tissue. KAI1 was observed in tumour cells as well
as in normal cells. The protein was localized on the cell
membrane and in the cytosol. Dark brown staining was
observed on the cell boundaries of normal cells indicating
the presence of KAI1. KAI1 protein was more abundantly
observed in mammary epithelial cells in unaffected tissues
(Fig. 1A left panel and B2a) as compared to cancer cells
(Fig. 1A right panel and B2b).
Expression of the KAI1 transcripts in breast cancer cells and
tissues. Conventional RT-PCR highlights alteration in KAI-1
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Figure 1. Immunohistochemical staining of KAI1 in frozen sections of unaffected normal mammary tissues and tumour tissues. (A) Comparison between
unaffected normal tissues (left panel, ID 136) and an invasive tumour (ID 111). (B) Comparison between residual mammary cells (B2a and B3a) and invasive
tumour cells (B2b and B3b) in the same sample (ID 113). Tumour cells showed a marked reduction of KAI1 staining compared with affected mammary
epithelial cells.
Figure 2. Expression of KAI1 transcripts in human mammary tissues. (A)
Expression pattern of KAI1 transcript by using conventional RT-PCR
(shown are PCR products separated by 2% agarose gel electrophoresis).
Almost complete loss of KAI1 mRNA is clearly evident in ductal breast
tumour samples in comparison to ß-actin which was used as internal control.
(B) KAI1 expression levels in normal and ductal breast tissue in the cohort
by quantitative real-time PCR analysis (shown are medians of KAI1/
GAPDH ratios). Ductal breast tissue samples showed a significant decrease
of KAI1 transcript in comparsion to normal tissue samples.
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expressional levels between paired normal and tumour tissues.
In majority of these paired samples KAI1 levels appear to be
reduced in the tumour tissue as compared to normal samples
as shown in Fig. 2A. Further verification was done through
quantitative real-time PCR that showed a decrease of KAI1
expression in all breast cancer samples as shown in Fig. 2B.
The data presented are after normalizing with GAPDH.
Correlation of KAI1 transcripts with nodal status, grade and
tumour staging. We were unable to identify any significant
correlation of KAI1 transcript level between grade 1 (well-
differentiated), grade 2 (moderately differentiated) and grade 3
(poorly differentiated) of invasive ductal breast cancer tissues.
No significant correlation with NPI (Nottingham Prognostic
Index) has been observed (Table II). Early stage breast
tumours (TNM1) had a significantly highly levels of KAI1
transcripts compared with late stage tumours (TNM2, 3 and 4)
(p=0.045, Fig. 3).
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Table II. Summary of KAI-1 transcript levels in the study cohort.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Group KAI1 transcript (median and IQR) p-value (Mann-Whitney U test)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Grade
1 0.0045 (IQR 0.003-0.0353)
2 0.002 (IQR 0-0.005 ) NS
3 0.003 (IQR 0-0.033) NS
NPI index
<3.4 0.002 (IQR 0-0.025 )
3.4-5.4 0.003 (IQR 0-0.016) NS
>5.4 0.041 (IQR 0.001-0.0335) NS
Clinical outcome
Disease free 0.004 (IQR 0.001-0.029)
With metastasis 0.02 (IQR 0-0.04) NS
With local recurrence 0.021 (IQR 0.006-.041) NS
Died of breast cancer <0.0001 (IQR 0-0.0008) p=0.0136 vs. disease-free
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aShown are median levels and interquartile range (IQR) of KAI1/GAPDH ratio in the respective group. NPI, Nottingham Prognostic Index;
NS, not significant.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. Correlation of KAI1 transcripts with tumour staging of ductal
breast cancer. Significant correlation of KAI1 transcript number normalized
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) against tumour,
node and metastasis (TNM) staging were observed (p=0.0455). Shown are
median and interquartile range (IQR) of KAI1/GAPDH ratio in the
respective group.
Figure 4. KAI1 transcript levels in ducal carcinoma linked to long-term
survival of the patients. (A) Graphical illustration of survival rate in patients
with KAI1 expression. Increase survival of breast cancer patients were
observed in patients showing strong KAI1 expression in comparison to
KAI1 negative patients. Shown are median and interquartile range (IQR) of
KAI1/GAPDH ratio in the respective group. (B) Kaplan-Meier survival
curve after 10 years of follow-up. Significant association of KAI1 level
(p=0.0136) based on KAI1/glyceraldehyde 3 phosphate dehydrogenase
(GAPDH) ratio indicating survival of patients with ductal carcinoma had
been observed. 
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Impact on patients survival. Patients who were disease-free
had a significantly higher levels of KAI1 transcripts than
those who died of breast cancer (p=0.0136, Fig. 4A). Using
the Kaplan-Meier survival model, we found that patients
with high levels of KAI1 transcripts had a significantly
longer survival [mean survival 152 (95% confident interval
144-160 months)] than patients with low level of KAI1 [120
(95%CI 104-137) months)] (p=0.0136) (Fig. 4B).
Discussion
Metastasis suppression character of KAI1 was first discovered
in prostate cancer which was later extrapolated in other types
of cancer. The most significant findings of the present study
are the correlation with KAI1 transcript and patients long-
term survival. After 10 years of follow-up it was observed
that patients showed a direct correlation between expression
of KAI1 and survival. Disease-free survival rate was signifi-
cantly higher in patients showing higher levels of KAI1 at
the initial stage of mammary tumours compared to those who
died as a result of cancer. This relationship of KAI1 expression
with patients survival rate was also mentioned (p=0.0091 in
62 patients) in an earlier study (21). Similarly in another study,
the 5-year disease-free survival rate of KAI1 positive tumour
patients was more than KAI1 negative tumour patients
(p=0.0292) (9). Disease-free survival rate of KAI1 positive
tissue has also been observed in relation to other types of
cancers such as epithelial ovarian carcinoma (22), lung
cancer (11), pancreatic cancer (15) and gastric cancer (12).
As overall survival rates of lung cancer patients was
significantly better in patients showing increased expression
of KAI1 compared to patients showing a decrease in KAI1 as
observed by Adachi et al (23). Similarly decreased level of
KAI1 protein in advance stage gastric cancer patients also
increase cancer-related death (12) providing a strong
evidential usage of KAI1 along with other markers as a
potential prognostic marker.
Decreased expression of KAI1 was consistently reported in
breast cancer progression (9,10,22,24) but significant cor-
relation with respect to clinical progression of breast cancer
stages was lacking. In a study on a Korean population Son et al
showed a consistent decrease of KAI1 in infiltrating ductal
carcinoma of breast but did not find any significant correlation
with clinicopathological features (21). In the present study, a
correlation of KAI1 with tumour node and metastasis system
was identified which may later along with other markers be
used as a better prognostic marker. These findings are also in
accordance with a previous study on lung cancer (25) indicating
a significant relationship with differentiated degree of tumour
TNM stages and lymph node metastasis.
Down-regulation of KAI1 is attributed more toward
expressional regulation rather than the involvement of coding
region mutations. As mentioned also in previous studies the
chance of somatic as well as germline mutations on coding
region of KAI1 molecule is an extremely rare event
(22,26,27). KAI1 molecule has a transmembrane localization
forming several interactions with integrin (28), chemokines
(29), EGFR (30) and other tetraspanin (31). Suppression of
cancer cells is actually induced by internalization of EGFR
and also by accelerating desensitization of EGF signalling
(5). These interactions are responsible for cell-cell
interaction, cell motility, and adhesion cell signalling.
Increased KAI1 level both at transcript and translational
scale actually reduce invasion of the breast cancer cells as
mentioned in several previous reports (32-34). Thus, down-
regulations of KAI1 both at transcript as well as translation
level in clinical cases ultimately lead to poor prognosis.
In conclusion, the association of KAI1 expression with
breast cancer progression is a potential prognostic candidate
marker. KAI1 metastatic suppression ability in conjunction
with other markers can also be used as a marker of thera-
peutic potential. Apart from clinical trials, the role of KAI1
in various cellular signalling pathways is an area that requires
further investigation.
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